Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection

The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. The bioengineered ACE2 (Tag-sACE2 and probiotic-ACE2) as a way may overcome its therapeutic lim...

Descripción completa

Detalles Bibliográficos
Autor principal: Maiti, Biplab K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589099/
https://www.ncbi.nlm.nih.gov/pubmed/34773078
http://dx.doi.org/10.1038/s41371-021-00636-y
_version_ 1784598628770250752
author Maiti, Biplab K.
author_facet Maiti, Biplab K.
author_sort Maiti, Biplab K.
collection PubMed
description The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. The bioengineered ACE2 (Tag-sACE2 and probiotic-ACE2) as a way may overcome its therapeutic limitations against ongoing current pandemic.
format Online
Article
Text
id pubmed-8589099
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85890992021-11-15 Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection Maiti, Biplab K. J Hum Hypertens Perspective The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. The bioengineered ACE2 (Tag-sACE2 and probiotic-ACE2) as a way may overcome its therapeutic limitations against ongoing current pandemic. Nature Publishing Group UK 2021-11-12 2022 /pmc/articles/PMC8589099/ /pubmed/34773078 http://dx.doi.org/10.1038/s41371-021-00636-y Text en © The Author(s), under exclusive licence to Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Perspective
Maiti, Biplab K.
Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection
title Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection
title_full Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection
title_fullStr Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection
title_full_unstemmed Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection
title_short Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection
title_sort bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against sars-cov-2 infection
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589099/
https://www.ncbi.nlm.nih.gov/pubmed/34773078
http://dx.doi.org/10.1038/s41371-021-00636-y
work_keys_str_mv AT maitibiplabk bioengineeredangiotensinconvertingenzyme2apotentialtherapeuticoptionagainstsarscov2infection

Ejemplares similares